3Mason JO 3rd, Colagross CT, Haleman T, Fuller JJ, White MF,Feist RM, et al. Visual outcome and risk factors for light perception and no light perception vision after vitrectomy for diabetic retinopathy [ J ]. Am J Ophthalmol,2005,140 ( 2 ) :231-235.
4Honavar SG, Goyal M, Maji AB, Sen PK, Naduvilath T, Dandona L. Glaucoma after pars plana vitrectomy and silicone oil injection for complicated retinal detachments [ J ]. Ophthalmology, 1999,106 ( 1 ) : 169-176.
5Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis[J]. Semin Ophthalmol,2009,24(2) :113-121.
6Ho CL, Wong EY, Chew PT. Effect of diode laser contact transscleral pars plana photocoagulation on intraocular pressure in glaucoma[J]. Clin Exp Ophthalmol,2002 ,30 ( 5 ) :343-347.
7Frezzotti P, Mittica V, Martone G, Motolese I, Lomurno L, Peruzzi S, et al. Longterm follow-up of diode laser transscleral cyclophotocoagulation in the treatment of refractory glaucoma [ J ]. Acta Ophthalmol,2010,88( 1 ) :150-155.
8Murphy CC, Burnett CA, Spry PG, Broadway DC, Diamond JP. A two centre study of the dose-response relation for transscleral diode laser cyclophotocoagulation in refractory glaucoma [J]. Br J Ophthalmol,2003 ,87 (10 ) :1252-1257.
9Van Wijngaarden P, Coster D J, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems [ J ]. JMMA,2005,293(12 ) :1509-1513.
10Funatsu H, Yamashita H, Noma H, Mimura T, Sakata K, Hori S. Risk evaluation of outcome of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin II[ J]. Br J Ophthalmol,2004, 88(9) :1064-1068.
